GLP-1-SM 20mg Description

GLP-1-SM (Semaglutide) is a synthetic 31-amino-acid analog of human glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone that regulates glucose metabolism and appetite. It is engineered from the native GLP-1(7-37) sequence with three key modifications: substitution of alanine at position 8 with α-aminoisobutyric acid (Aib) for protease resistance, a C18 fatty diacid chain conjugated at Lys26 via a gamma-glutamic acid and mini-PEG linker for albumin binding, and a Lys-to-Arg substitution at position 34. Together these modifications extend the circulating half-life from roughly 2 minutes (native GLP-1) to approximately 7 days, enabling once-weekly research dosing.

GLP-1-SM works by binding and activating the GLP-1 receptor (GLP-1R) through the cAMP/PKA pathway. On pancreatic β-cells it enhances glucose-dependent insulin secretion while suppressing glucagon release, lowering blood glucose without driving hypoglycemia. In the hypothalamic arcuate nucleus it stimulates POMC neurons and inhibits AgRP/NPY signaling to reduce appetite, and it delays gastric emptying to prolong satiety. Additional studied effects include modulation of lipid metabolism and systemic inflammatory signaling.

Semaglutide is one of the most extensively characterized GLP-1 receptor agonists in modern metabolic research, with a deep clinical trial record spanning glycemic control, body weight, and cardiovascular outcomes. It is studied here strictly as a research peptide.

Peptide Information

Lyophilized Peptides:

These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage. We do not use any fillers in this process. GLP-1-SM should be stored refrigerated and protected from light; keep reconstituted solution refrigerated.

Sealed Vial: 20mg of Lyophilized Powder in 3ml Vial

CAS No.: 910463-68-2

Other Names: Semaglutide, NNC 0113-0217, GLP-1 (7-37) analog (Acetate)

This Product is Not For Human Consumption and is for Laboratory Use Only. Please Read our Terms and Conditions.

Disclaimer: For Research Purposes Only
This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides.

GLP-1-SM Research

The following sections explore the diverse applications and mechanisms of GLP-1-SM (Semaglutide) across multiple research domains. As one of the most thoroughly characterized GLP-1 receptor agonists, it has an exceptionally deep clinical and preclinical research record in metabolic science.

This overview synthesizes key findings on its receptor mechanism and research applications in glycemic regulation, body weight, and cardiovascular outcomes.

GLP-1 Receptor Mechanism

Semaglutide is a long-acting GLP-1 receptor agonist whose pharmacology derives from its engineered stability. The Aib8 substitution confers DPP-IV resistance while the Lys26 fatty-diacid modification produces high-affinity albumin binding, together extending half-life to roughly one week and enabling sustained receptor engagement — the structural basis for its research utility as a durable GLP-1R probe¹.

Glycemic and Cardiovascular Outcomes Research

Among the most cited findings is the SUSTAIN-6 trial, a large randomized placebo-controlled study in patients with type 2 diabetes, which reported that semaglutide significantly reduced the rate of major adverse cardiovascular events alongside improvements in glycemic measures — establishing the GLP-1R agonist class as cardiometabolically active beyond glucose lowering².

Body Weight Research

The STEP 1 trial, a randomized placebo-controlled study in adults with overweight or obesity without diabetes, reported substantial and sustained mean weight reduction of approximately 14.9% with once-weekly semaglutide plus lifestyle intervention, with 86% of participants achieving at least 5% reduction — one of the most influential datasets in metabolic research³.

Cardiovascular Outcomes in Non-Diabetic Populations

The SELECT trial extended this work to a non-diabetic population, reporting that in adults with overweight or obesity and pre-existing cardiovascular disease, semaglutide produced a significant reduction in major adverse cardiovascular events — distinguishing the compound’s cardiovascular effects from its glycemic activity⁴.

Research Considerations

Across the clinical literature, the most commonly reported effects are gastrointestinal (nausea, vomiting, diarrhea, constipation), generally dose-dependent and associated with titration. Research framing in the metabolic literature increasingly emphasizes that GLP-1R agonists are studied as cellular and metabolic modulators rather than isolated appetite agents, with study designs accounting for dose escalation and tolerability. These considerations are routinely accounted for within controlled study protocols.

References

1. Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155
2. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
4. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563